(VNDA) Vanda Pharmaceuticals Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VNDA) Vanda Pharmaceuticals Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Vanda Pharmaceuticals Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
HETLIOZ rare sleep-disorder franchise
HETLIOZ is Vanda Pharmaceuticals Inc.’s clearest Stars asset: it is FDA-approved for non-24-hour sleep-wake disorder, a rare condition that affects about 50% to 80% of totally blind people. Orphan status helps support premium pricing and tight, specialist prescribing. Label expansion could widen the base beyond one niche and keep this franchise Vanda’s main growth engine.
Fanapt long-acting injectable schizophrenia
Fanapt long-acting injectable targets schizophrenia’s big adherence gap, where about 40% to 60% of patients stop oral antipsychotics. Long-acting injectables are still a growth niche in CNS, and they can cut relapse and rehospitalization costs. If Vanda Pharmaceuticals Inc. wins the launch, it adds a higher-growth layer to Fanapt and becomes a major upside driver.
Tradipitant gastroparesis
Tradipitant targets gastroparesis, a GI market with high unmet need and few approved options, so even modest efficacy can matter. Late-stage data could support fast share gains because patients still face nausea, vomiting, and poor quality of life. In Vanda Pharmaceuticals Inc.'s BCG Matrix, it fits a high-growth pipeline bet with Star potential.
VTR-297 hematologic malignancies
VTR-297 in hematologic malignancies sits in a high-spend oncology lane; global oncology drug sales are already above $200 billion, so even a small share can matter. Blood cancers also support premium pricing when response data are strong, because relapse and chronic use can lift lifetime value. If Vanda Pharmaceuticals Inc. shows clear differentiation, this asset could reach a much larger commercial pool than a niche CNS program. That makes it a real star candidate, but only if late-stage data hold up.
- Large oncology spend pool
- Premium pricing possible
- Broader commercial reach
- Star if data succeed
VQW-765 psychiatric disorders
VQW-765 fits a large psychiatry market, where chronic disorders like depression, schizophrenia, and bipolar disorder drive recurring treatment. If it shows strong safety and efficacy, adoption could be fast because clinicians switch quickly in high-unmet-need CNS space. For Vanda Pharmaceuticals Inc., it remains one of the clearest growth options in the portfolio.
- Large recurring CNS demand
- High unmet need supports uptake
- Best-in-class data could accelerate use
Vanda’s Star Drugs Target Rare, Hard-to-Treat Markets
Vanda Pharmaceuticals Inc.’s Stars are led by HETLIOZ, Fanapt LAI, Tradipitant, VTR-297, and VQW-765 because each sits in a niche with strong unmet need and pricing power. HETLIOZ serves a rare disorder affecting about 50% to 80% of totally blind people, while CNS and oncology assets can scale in larger pools. Success in late-stage data is the key trigger.
| Asset | Star case |
|---|---|
| HETLIOZ | Rare disease, premium pricing |
| Fanapt LAI | Adherence gap, CNS growth |
| Tradipitant | Few GI options, late-stage upside |
What is included in the product
Detailed Word Document
Vanda Pharmaceuticals’ BCG Matrix maps its drugs by growth and market share, highlighting invest, hold, or divest priorities.
Editable Excel File
One-page BCG Matrix for Vanda Pharmaceuticals, instantly showing each business unit’s quadrant and strategic priority.
Reference Sources
Provides a credible source trail for Vanda Pharmaceuticals Inc., making key claims easier to verify and decisions easier to defend.
Cash Cows
HETLIOZ non-24 oral capsules
HETLIOZ non-24 oral capsules are a classic cash cow for Vanda Pharmaceuticals Inc.: the core 20 mg oral dose is already approved and commercialized, so spending stays modest versus launch-stage drugs. Non-24 in totally blind adults is a rare, clinically defined market, which keeps promotion narrow and prescribing steady. Mature demand can keep producing cash instead of consuming it.
Fanapt oral tablets
Fanapt oral tablets are approved for schizophrenia and sit in a mature oral antipsychotic market where repeat prescriptions drive steady demand. That makes the brand a low-spend, recurring cash generator for Vanda Pharmaceuticals Inc. In 2025, this kind of established product typically needs far less launch spend than new drugs, which fits the cash cow profile.
2 approved brands
Vanda Pharmaceuticals Inc. runs on 2 approved brands, Fanapt and Hetlioz, so its commercial base is narrow and easier to manage.
That small portfolio lowers selling and operating complexity, which helps protect margins while the brands stay mature.
Cash from these 2 products is best harvested, not pushed for fast growth, and it helps fund Vanda Pharmaceuticals Inc.’s pipeline.
US commercial sales base
US commercial sales remain Vanda Pharmaceuticals Inc.'s main cash cow: domestic product sales are the company’s most mature channel and the biggest share of revenue. Strong payer access and brand recognition help keep cash generation efficient, while the business looks low growth and more about harvesting than expansion.
- Most established revenue engine
- Strong U.S. payer coverage
- High brand awareness supports demand
- Low-growth, cash-rich asset
Europe and Israel sales base
Vanda’s Europe and Israel sales base fits Cash Cows: approved products keep earning with little new-launch spend. In 2025, the company posted about $217.7 million in total net product sales, so these markets help extend the life of existing brands while keeping capital needs light.
That makes the region a harvest engine, not a hypergrowth bet.
- Broadens reach without heavy launch costs
- Supports longer product life cycles
- Cash generation over rapid expansion
Vanda’s Cash Cows Keep Cash Flowing
Vanda Pharmaceuticals Inc.’s Cash Cows are Fanapt and Hetlioz: two approved, mature brands that need little launch spend and keep recurring cash flowing. In 2025, Vanda Pharmaceuticals Inc. reported about $217.7 million in total net product sales, showing a stable harvest base. U.S. sales and select ex-U.S. markets support this low-growth, cash-rich profile.
| 2025 data | Value |
|---|---|
| Total net product sales | $217.7 million |
| Core cash cows | Fanapt, Hetlioz |
Full Version Awaits
Vanda Pharmaceuticals Inc. Reference Sources
You’re previewing the exact Vanda Pharmaceuticals Inc. BCG Matrix document you’ll receive after purchase. No demo content or placeholders—just the final, fully formatted report. Once purchased, the same file is ready for download, editing, or presentation. It’s a clean, analysis-ready asset for strategic planning.
Dogs
VHX-896 iloperidone metabolite
VHX-896 is the active metabolite of iloperidone, so it sits almost entirely inside the Fanapt franchise rather than opening a new market. That overlap makes it a clear Dogs case in Vanda Pharmaceuticals Inc.'s BCG Matrix. With no separate 2025 revenue stream and no disclosed standalone sales, its strategic value looks weak versus the core commercial asset.
BPO-27 secretory diarrhea
BPO-27 targets secretory diarrhea disorders, including cholera, but the market is episodic and tied to outbreaks, so demand can swing fast. Global cholera cases reported to WHO reached 535,000+ in 2024, yet this is still a narrow, event-driven market. That makes development economics weaker than Vanda Pharmaceuticals Inc.'s larger CNS or oncology bets, with low share and limited repeat revenue support, so it fits a dog-like asset.
CFTR dry-eye and ocular inflammation
Vanda Pharmaceuticals Inc.'s CFTR activator and inhibitor set targets ocular disease, but dry eye and ocular inflammation are crowded arenas with many approved and pipeline rivals. Vanda has no proven commercial scale here yet, so the franchise stays in low-share territory. In BCG terms, that points to a Question Mark: high contest, no clear 2025/2026 revenue base, and roughly 0% meaningful market share.
Tradipitant atopic dermatitis
Atopic dermatitis is a crowded market, with roughly 10% to 20% of children and 2% to 10% of adults affected, so Tradipitant needs clear efficacy or safety edge to win. Without a sharp lead, share is hard to build, and that makes it a weak-fit Dogs asset in Vanda Pharmaceuticals Inc.'s BCG Matrix.
- Competitive dermatology is hard to penetrate.
- Differentiation must be obvious and durable.
- Weak share potential limits investment appeal.
Legacy non-core preclinical set
Vanda Pharmaceuticals Inc.’s legacy preclinical set fits the Dog bucket because it sits outside the company’s core commercial engine and still burns R&D cash before any proof of value. In 2025, Vanda reported $150.4 million in revenue and $92.8 million in R&D expense, so even small early-stage programs can pressure returns if they do not move forward.
- Outside core sales base
- High cash burn before data
- Failed assets become sunk costs
That is classic dog risk: low current value, uncertain odds, and capital tied up in programs that may never scale.
Vanda’s Old Assets: High Cash Drain, No Revenue Engine
VHX-896, BPO-27, and Vanda Pharmaceuticals Inc.'s older preclinical assets all fit Dogs: low share, weak or episodic demand, and no clear 2025/2026 revenue engine. Vanda Pharmaceuticals Inc. reported $150.4 million revenue and $92.8 million R&D in 2025, so these programs tie up cash without proven scale.
| Asset | Dog signal | 2025 data |
|---|---|---|
| VHX-896 | No standalone sales | 0 revenue |
Question Marks
HETLIOZ Smith-Magenis syndrome
HETLIOZ in Smith-Magenis syndrome is a Question Mark because it is a label-expansion play, not a mature market. Smith-Magenis syndrome is ultra-rare, affecting about 1 in 15,000 to 25,000 people, and remains underserved, so success could open a new revenue stream for Vanda Pharmaceuticals Inc. Until approval and uptake are proven, HETLIOZ’s share in this use case is still untested.
HETLIOZ pediatric Non-24
HETLIOZ pediatric Non-24 is a BCG "question mark": the addressable pool is small, but the unmet need in blind children with Non-24 is real. The franchise could broaden if Vanda Pharmaceuticals Inc. wins more pediatric use, yet adoption stays uncertain because this niche needs physician awareness, payer support, and long follow-up. It will need more investment before it can become a meaningful revenue driver.
Fanapt bipolar disorder
Fanapt in bipolar disorder is a classic question mark: the bipolar I market affects about 2.8% of U.S. adults each year, but Fanapt has proven sales only in schizophrenia. In Vanda Pharmaceuticals Inc.’s 2025 set-up, share in bipolar is still unproven, so the drug needs clear efficacy data and differentiation before it can win meaningful CNS revenue.
Tradipitant motion sickness
Tradipitant for motion sickness sits in a broad, episodic-use market where a strong Phase 3 readout could drive quick uptake, but it still has no established share and no disclosed 2025 revenue. The bet is high risk, because adoption would depend on clear efficacy, clean safety, and a fast launch. If it works, the addressable use case is large and repeatable.
- Broad episodic-use market
- No established share yet
- Fast uptake if efficacy is strong
- High-risk growth bet
Jet lag disorder expansion
Jet lag disorder expansion sits in a larger travel sleep market, but Vanda Pharmaceuticals Inc. must turn HETLIOZ’s known melatonin-pathway mechanism into new demand. The idea is growth-led, yet it is still unproven because success depends on regulatory wins and real-world adoption.
Until that happens, it remains a question mark in the BCG matrix: attractive upside, weak current proof. One clear signal: the jet lag use case is far bigger than HETLIOZ’s current narrow base, but it has not yet translated into approved revenue.
- Large travel-linked sleep market
- Mechanism is known, demand is not
- Upside depends on approval
- Still a question mark
Vanda’s 2025 Upside Hinges on Three Unproven Growth Bets
Vanda Pharmaceuticals Inc.’s question marks are HETLIOZ in Smith-Magenis syndrome and pediatric Non-24, Fanapt in bipolar disorder, and tradipitant or jet lag expansion: each has real demand, but 2025 share and revenue proof are still thin. The upside is clear, but each program still needs clinical, regulatory, and payer wins.
| Asset | 2025 status | Why a question mark |
|---|---|---|
| HETLIOZ SMS | Unproven | Label expansion |
| Fanapt bipolar | Unproven | No share yet |
| Tradipitant | No revenue | Launch risk |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.